Pharmacokinetics of Ocriplasmin in Vitreous

Smet, Marc D. de; Jonckx, Bart; Vanhove, Marc; Calster, Joachim Van; Stalmans, Peter; Stassen, Jean Marie

doi:10.1167/iovs.12-10148

Cited by 21 publications

(13 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Pharmacological vitreolysis has been studied as an alternative to vitrectomy and has become a promising medical agent because of its ability to induce PVD, for its stable structure, and as a supplement to observation and vitrectomy in managing selected disorders (5)(6)(7)(8)10) . Previous studies have demonstrated that appropriate patient selection is critical for improving outcomes using ocriplasmin (5)(6)(7)(8)10) .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Initial experience with ocriplasmin in the treatment of vitreomacular traction

Garcia¹,

Isaac²,

Ávila³

2016

Arquivos Brasileiros De Oftalmologia

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

“…Previous studies have demonstrated that appropriate patient selection is critical for improving outcomes using ocriplasmin (5)(6)(7)(8)10) . The overall frequency of successful release (4 eyes, 57.1%) was higher in this study than in phase III clinical trials (26.5%).…”

Section: Discussionmentioning

confidence: 99%

Initial experience with ocriplasmin in the treatment of vitreomacular traction

Garcia¹,

Isaac²,

Ávila³

2016

Arquivos Brasileiros De Oftalmologia

View full text Add to dashboard Cite

“…27,28 Its biological activity within the vitreous cavity can be observed no longer than several days post-injection. 31 The drug is available in solution for injection. It is designed for intravitreal use under aseptic controlled conditions.…”

Section: Pharmacological Treatment Of Symptomatic Vmamentioning

confidence: 99%

Intravitreal ocriplasmin: A breakthrough in the treatment of vitreomacular traction?

Mec-Słomska

Adamiec-Mroczek²,

Kuźmicz³

et al. 2017

Adv Clin Exp Med

View full text Add to dashboard Cite

Vitreoretinal interface pathologies, such as vitreomacular traction syndrome, epiretinal membranes and macular holes are sight-threatening conditions and one of the important causes of vision defects and vision loss. To this date, vigilance with observation of how the vitreomacular traction resolves, or vitreoretinal surgery in more severe cases, were the only treatment options. Recent rapid progress in ophthalmology, especially in diagnostic and visualization techniques, provided better insight into the mechanisms taking place on the vitreoretinal surface, which enabled a more accurate selection of treatment options. Development of ophthalmic pharmacological procedures, such as treatment of vitreomacular traction syndrome with ocriplasmin, constitutes an innovative breakthrough in ophthalmology. The enzyme is a genetically engineered form of human plasmin, a component of blood coagulation cascade that has been envisioned for human therapy since 1950s. It has never been used for vitreolysis in ophthalmology before. The aim of this review is to analyze and compare therapeutic options for symptomatic vitreomacular adhesion and vitreoretinal traction, with particular emphasis on microplasmin. We reviewed the results of recent studies comparing ocriplasmin to other widespread treatment options, such as pars plana vitrectomy.

show abstract

“…It then enters the endogenous protein catabolism pathway, limiting its biological duration of activity to several days after injection which varies based on the presence and concentration of serine protease inhibitors [17].…”

Section: Pharmacokinetics and Metabolismmentioning

confidence: 99%

Ocriplasmin opens up new avenues in the therapy of vitreomacular traction

Schmit-Eilenberger¹,

Augustin²

2013

Expert Review of Ophthalmology

View full text Add to dashboard Cite

Until now, the only treatment available for severe symptomatic vitreomacular traction, has been pars-plana-vitrectomy. Now, there is evidence for a new minimally invasive surgical therapy: the results of two Phase III studies show that an intravitreal injection of ocriplasmin allows an enzymatic vitreolysis. KEYWORDS: enzymatic vitreolysis • intravitreal injection • macular holes • minimal invasive surgery • ocriplasmin • pars-plana-vitrectomy • plasmin • posterior vitreous detachment • recombinant protease • vitreomacular adhesion • vitreomacular traction • vitreous body

show abstract

Pharmacokinetics of Ocriplasmin in Vitreous

Abstract: Ocriplasmin is autolytic in vitreous. Biologic activity extends to several days following injection. The exact duration will vary based on the presence and concentration of serine protease inhibitors.

Cited by 21 publications

References 21 publications

Initial experience with ocriplasmin in the treatment of vitreomacular traction

Initial experience with ocriplasmin in the treatment of vitreomacular traction

Intravitreal ocriplasmin: A breakthrough in the treatment of vitreomacular traction?

Ocriplasmin opens up new avenues in the therapy of vitreomacular traction

Contact Info

Product

Resources

About